Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

WIN 2014 Symposium

Industry view of targeted therapy combinations in oncology

Dr Susan Galbraith – AstraZeneca, Macclesfield, UK

Industry view of targeted therapy combinations in oncology ( Dr Susan Galbraith – AstraZeneca, Macclesfield, UK )

Impact of biomarker-integrated approaches of targeted therapy for lung cancer elimination

Prof Waun Ki Hong - University of Texas MD Anderson Cancer Center, Houston, USA

Impact of biomarker-integrated approaches of targeted therapy for lung cancer elimination ( Prof Waun Ki Hong - University of Texas MD Anderson Cancer Center, Houston, USA )

Networking and collaborating across borders in sub-Saharan Africa

Dr Shubhra Ghosh - Project Director of Global Programs, MD Anderson Cancer Centre, Houston, USA

Networking and collaborating across borders in sub-Saharan Africa ( Dr Shubhra Ghosh - Project Director of Global Programs, MD Anderson Cancer Centre, Houston, USA )

Genomic complexity of metastatic disease and the conundrum of combinations

Prof Razelle Kurzrock - University of California, San Diego, USA

Genomic complexity of metastatic disease and the conundrum of combinations ( Prof Razelle Kurzrock - University of California, San Diego, USA )

Complexity of intra- and inter-pathway loops in colon cancer and melanoma: Implications for targeted therapies

Prof René Bernards - Netherlands Cancer Institute, Amsterdam, The Netherlands

Complexity of intra- and inter-pathway loops in colon cancer and melanoma: Implications for targeted therapies ( Prof René Bernards - Netherlands Cancer Institute, Amsterdam, The Netherlands )

WIN consortium as a basis for forming cross-border collaborations for improving personalised medicine and palliative care

Dr Oliver Bogler - MD Anderson Cancer Center, Houston, USA

WIN consortium as a basis for forming cross-border collaborations for improving personalised medicine and palliative care ( Dr Oliver Bogler - MD Anderson Cancer Center, Houston, USA )

Systems medicine approach to optimise drugs and drug combinations for individual AML patients

Dr Olli Kallioniemi - University of Helsinki, Helsinki, Finland

Systems medicine approach to optimise drugs and drug combinations for individual AML patients ( Dr Olli Kallioniemi - University of Helsinki, Helsinki, Finland )

Work of the WIN consortium and challenges of personalised cancer therapy

Prof John Mendelsohn - University of Texas MD Anderson Cancer Center, Houston, USA

Work of the WIN consortium and challenges of personalised cancer therapy ( Prof John Mendelsohn - University of Texas MD Anderson Cancer Center, Houston, USA )

Tumour-infiltrating immune cells as classifiers and predictors of outcome

Dr Jérôme Galon - Laboratory of Integrative Cancer Immunology, Paris, France

Tumour-infiltrating immune cells as classifiers and predictors of outcome ( Dr Jérôme Galon - Laboratory of Integrative Cancer Immunology, Paris, France )

Proactive P4 medicine making blood a window into health and disease

Prof Leroy Hood - Systems Biology, Seattle, USA

Proactive P4 medicine making blood a window into health and disease ( Prof Leroy Hood - Systems Biology, Seattle, USA )

Molecular investigations of immune cells and tumour environment: The ovarian cancer model

Dr George Coukos - Ludwig Center for Cancer Research, Epalinges, Switzerland

Molecular investigations of immune cells and tumour environment: The ovarian cancer model ( Dr George Coukos - Ludwig Center for Cancer Research, Epalinges, Switzerland )

Growing tissue stem cells into organoids and tumeroids: Predictive assay development

Prof Hans Clevers - Hubrecht Institute, Utrecht, The Netherlands

Growing tissue stem cells into organoids and tumeroids: Predictive assay development ( Prof Hans Clevers - Hubrecht Institute, Utrecht, The Netherlands )

Combining immunological and targeted agents in melanoma

Dr Axel Hoos - GlaxoSmithKline, Collegeville, USA

Combining immunological and targeted agents in melanoma ( Dr Axel Hoos - GlaxoSmithKline, Collegeville, USA )

Perspectives for effective cancer drug development: The EORTC SPECTA Initiative

Dr Denis Lacombe - EORTC, Brussels, Belgium

Perspectives for effective cancer drug development: The EORTC SPECTA Initiative ( Dr Denis Lacombe - EORTC, Brussels, Belgium )

Cancer stem cells and malignant progression

Prof Rob Weinberg - Massachusetts Institute of Technology, Cambridge, USA

Cancer stem cells and malignant progression ( Prof Rob Weinberg - Massachusetts Institute of Technology, Cambridge, USA )

Colorectal cancer screening and the EORTC SPECTA initiative

Dr Sabine Tejpar - University of Leuven, Leuven, Belgium

Colorectal cancer screening and the EORTC SPECTA initiative ( Dr Sabine Tejpar - University of Leuven, Leuven, Belgium )

microRNA replacement in malignant pleural mesothelioma

Dr Glen Reid - The University of Sydney, Sydney, Australia

microRNA replacement in malignant pleural mesothelioma ( Dr Glen Reid - The University of Sydney, Sydney, Australia )

Personalised cancer medicine using the human protein atlas and affibodies

Prof Mathias Uhlén - Royal Institute of Technology (KTH), Stockholm, Sweden

Personalised cancer medicine using the human protein atlas and affibodies ( Prof Mathias Uhlén - Royal Institute of Technology (KTH), Stockholm, Sweden )

ARC Foundation's work and aims

Dr Jacques Raynaud - Foundation ARC pour la Recherche Cancer, Villejuif, France

ARC Foundation's work and aims ( Dr Jacques Raynaud - Foundation ARC pour la Recherche Cancer, Villejuif, France )

IDH1 mutation in haemato-oncology

Dr Christof von Kalle - German Cancer Research Center (DKFZ), Heidelberg, Germany

IDH1 mutation in haemato-oncology ( Dr Christof von Kalle - German Cancer Research Center (DKFZ), Heidelberg, Germany )

EORTC fosters move towards tailored cancer treatment through the SPECTA initiative in colorectal cancer

Prof Roger Stupp - President of the European Organization for Research and Treatment of Cancer (EORTC)

EORTC fosters move towards tailored cancer treatment through the SPECTA initiative in colorectal cancer ( Prof Roger Stupp - President of the European Organization for Research and Treatment of Cancer (EORTC) )

Novel drug targets and potential combinations in childhood brain tumours

Dr Stefan Pfister - German Cancer Research Center (DKFZ), Heidelberg, Germany

Novel drug targets and potential combinations in childhood brain tumours ( Dr Stefan Pfister - German Cancer Research Center (DKFZ), Heidelberg, Germany )

More from ecancer